The war on cancer : an anatomy of failure, a blueprint for the future
著者
書誌事項
The war on cancer : an anatomy of failure, a blueprint for the future
Springer, c2008
大学図書館所蔵 全1件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
注記
Includes bibliographical references (p. 185-208) and index
内容説明・目次
内容説明
After reviewing the history of cancer and its impact on the population, Dr. Faguet exposes the antiquated notions that have driven cancer drug development, documents the stagnation in treatment outcomes despite major advances in cancer genomics and growing NCI budgets, and identifies the multiple factors that sustain the status quo. He shows that, contrary to frequent announcements of breakthroughs, our current cancer control model cannot eradicate most cancers and the reasons why. Significantly, this book also delineates a way forward via a shift from the discredited cell-kill approach of the past to an integrated, evidence-driven cancer control paradigm based on prevention, early diagnosis, and pharmacogenomics. The author's views are based on data published in mainstream scientific journals and other reliable references, 432 of which are cited.
目次
Introduction Part I Cancer Statistics: Some Facts Chapter 1 Assessing the magnitude of the problem Chapter 2 The problem is growing, not going away Part II What Is Cancer? Chapter 3 Cancer through the ages Chapter 4 Our current understanding Part III How Is Cancer Treated? Chapter 5 The cancer-cell kill paradigm: Hypotheses and corollaries Chapter 6 Chemotherapy drugs Chapter 7 Treatment outcomes: Dismal by any standard Part IV Why Does This System Persist? Chapter 8 The role of the National Cancer Institute Chapter 9 Publications: The facts and nothing but the facts? Chapter 10 From the doctors' perspective Chapter 11 From the patients' perspective Part V Where Do We Go From Here? Chapter 12 A vision for the future Chapter 13 Shifting from the cell-kill paradigm to molecular therapies
「Nielsen BookData」 より